Cambrex (NYSE:CBM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm currently has a $67.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.45% from the company’s previous close.
According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
Several other research analysts have also issued reports on CBM. ValuEngine lowered Cambrex from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Craig Hallum lowered Cambrex from a “buy” rating to a “hold” rating and set a $60.00 target price on the stock. in a research report on Monday, August 12th. Finally, William Blair lowered Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research report on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Cambrex presently has a consensus rating of “Hold” and a consensus target price of $54.83.
Several hedge funds have recently made changes to their positions in CBM. Marshall Wace LLP acquired a new position in shares of Cambrex in the first quarter valued at about $30,000. Nordea Investment Management AB increased its holdings in shares of Cambrex by 4.5% in the first quarter. Nordea Investment Management AB now owns 72,310 shares of the biotechnology company’s stock valued at $2,809,000 after purchasing an additional 3,095 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Cambrex in the second quarter valued at about $437,000. Scout Investments Inc. increased its holdings in shares of Cambrex by 63.9% in the second quarter. Scout Investments Inc. now owns 141,929 shares of the biotechnology company’s stock valued at $6,644,000 after purchasing an additional 55,333 shares during the period. Finally, First National Bank of Omaha increased its holdings in shares of Cambrex by 6.7% in the second quarter. First National Bank of Omaha now owns 50,733 shares of the biotechnology company’s stock valued at $2,375,000 after purchasing an additional 3,189 shares during the period.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Story: Options Trading – Understanding Strike Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.